Immuno-Oncology

NANJING, China — August 25, 2026 Leads Biolabs announced that its proprietary Opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody, has...

Hong Kong, August 21, 2026 Akeso, Inc. has announced that its investigational B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received...

Cambridge, Massachusetts; Rotterdam, Netherlands; and Shanghai, China, August 18, 2026 Harbour BioMed (HKEX: 02142) announced that China’s National Medical...

Milwaukee, Wisconsin, August 17, 2026 The Society for Immunotherapy of Cancer (SITC) has announced the 2026 Class of Fellows...

Cambridge, UK — August 17, 2026 AstraZeneca announced that it is discontinuing the eVOLVE-Lung02 Phase III trial evaluating volrustomig...

China & Singapore, August 13, 2026 IASO Biotechnology has completed the acquisition of MediSix Therapeutics, a Singapore-based immune cell...

Shanghai, China, August 14, 2026 Aurisco Pharmaceutical announced that its Yangzhou, China manufacturing facility has successfully completed a U.S....

San Diego, California, August 14, 2026 Phanes Therapeutics, Inc., a clinical-stage biotechnology company focused on immuno-oncology drug discovery and...

San Diego, California, USA, August 8, 2026 Neurocrine Biosciences, Inc. has initiated a Phase 1 first-in-human clinical study evaluating...

Toronto, Ontario, Canada, August 8, 2026 Regeneron Canada Company announced that Health Canada has approved Libtayo® (cemiplimab for injection)...